Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau129pxo

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 4	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 5	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 6	FEB 10	COMPENDEX reloaded and enhanced
NEWS 7	FEB 11	WTEXTILES reloaded and enhanced
NEWS 8	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 9	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 10	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 11	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 12	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 13	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 14	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 15	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 16	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 17	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 18	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 19	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China
NEWS 20	MAR 30	IMSPATENTS reloaded and enhanced
NEWS 21	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS 22	APR 07	STN is raising the limits on saved answers
NEWS 23	APR 24	CA/CAplus now has more comprehensive patent assignee information
NEWS 24	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS 25	APR 28	CAS patent authority coverage expanded
NEWS 26	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced

NEWS 27 APR 28 Limits doubled for structure searching in CAS REGISTRY

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:29:50 ON 04 MAY 2009

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 16:30:22 ON 04 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 MAY 2009 HIGHEST RN 1141929-94-3
DICTIONARY FILE UPDATES: 3 MAY 2009 HIGHEST RN 1141929-94-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10511661a.str

L1 STRUCTURE UPLOADED

```
=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 16:38:24 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    61730 TO ITERATE

  3.2% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:      1219779 TO  1249421
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> search l1
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 16:38:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  1238081 TO ITERATE

100.0% PROCESSED  1238081 ITERATIONS                              32 ANSWERS
SEARCH TIME: 00.00.09

L3           32 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               192.12     192.34

FILE 'CAPLUS' ENTERED AT 16:38:45 ON 04 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 4 May 2009  VOL 150 ISS 19
FILE LAST UPDATED: 3 May 2009  (20090503/ED)
```

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 18 L3

=> d l4 fbib ab hitstr 1-18

L4 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2009:335387 CAPLUS
DN 150:352341
TI Increasing the in vivo biological activity of biologically active compounds
IN Jansen, Frans Herwing; Soomro, Shahid Ahmed
PA Dafra Pharma N.V., Belg.
SO PCT Int. Appl., 45pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009033706	A1	20090319	WO 2008-EP7556	20080910
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
				WO 2007-EP7868	A 20070910
	WO 2009033494	A1	20090319	WO 2007-EP7868	20070910
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PATENT FAMILY INFORMATION:

FAN 2009:335463

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2009033494	A1	20090319	WO 2007-EP7868	20070910

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

WO 2009033706	A1	20090319	WO 2008-EP7556	20080910

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

			WO 2007-EP7868	A 20070910

OS CASREACT 150:352341

AB The present invention relates to compds. with an increased in vivo biol. activity, and especially an increased pharmaceutical activity, such as an antinematodal or antifungal activity, an immunosuppresive activity, a metabolism influencing activity and/or an anticancer activity. Specifically, the present invention relates to a compound comprising an artemisinin derivative I covalently linked at the 1 or the 2 position to a compound with a biol. activity, or a pharmaceutically acceptable salt thereof, thereby increasing the biol. activity of said compound Compds. II [R1, R2 = H, XR3; R3 = biol. active compound; X = S, O, OC(:O), N] are prepared by reaction of dihydroartemisinin (III) with R3XH or R3XNa in Et2O containing BF3·OEt2. Thus, mercaptobenzimidazolylcarbamate IV was prepared from Me N-(5-mercaptobenzimidazol-2(1H)-yl)carbamate via reaction with Na in NH3 followed by reaction with dihydroartemisinin in Et2O containing BF3·OEt2.

IT 84210-35-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with dihydroartemisinin; increasing the in vivo biol. activity of biol. active compds. by conjugation with artemisinin)

RN 84210-35-5 CAPLUS

CN Phenol, 2-(aminomethyl)-3,5-bis(1,1-dimethylethyl)- (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2009:139449 CAPLUS
DN 150:191527
TI Preparation of fused bicyclic compounds as regulators of mineralocorticoid receptor (MR)
IN Takahashi, Yoichi; Awai, Nobumasa; Akatsuka, Hidenori; Kawaguchi, Takayuki; Iijima, Toru
PA Mitsubishi Tanabe Pharma Corporation, Japan
SO PCT Int. Appl., 134pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2009017190	A1	20090205	WO 2008-JP63751	20080731
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
			JP 2007-200264	A 20070801

OS MARPAT 150:191527
AB There are disclosed compds. such as benzoxazine and chromene derivs. represented by the formula [I; the ring A represents a benzene ring which is fused with the adjacent heterocyclic 6-membered ring and has a substituent R1, and which may have a substituent other than R1; R1 = alkylsulfonylamino, alkylaminosulfonyl; R2, R3 = H, alkyl, (un)substituted aryl; or R2 and R3 together form an oxo, or together with the adjacent carbon atom, form a cycloalkyl; X = N, C(R4), CH(R4); R4 = H, cyano, halo, alkyl, alkenyl, cycloalkyl, alkanoyl, carbamoyl, cycloalkenyl; Ar = (un)substituted aromatic cyclic group; and a dotted line means the presence or absence of a double bond] or pharmacol. acceptable salts thereof. These compds. have affinity for a mineralocorticoid receptor (MR) and are useful as mineralocorticoid receptor antagonists or aldosterone agonists for the prevention and/or treatment of various diseases or conditions caused by increase in activity of mineralocorticoid receptor and/or increase in level of aldosterone. They are useful as diuretics and for the prevention and/or treatment of hypertension, heart failure, myocardial infarction, angina pectoris, cardiac hypertrophy, myocardial fibrosis,

vascular fibrosis, baroreceptor disorder, body fluid excess, arrhythmia, primary or secondary aldosteronism, Addison's disease, Cushing syndrome, or Bartter syndrome. Thus, a solution of 101 mg 4-(4-chlorophenyl)-2,2-dimethyl-2H-1,3-benzoxazin-7-amine in 8 mL CHCl3 was treated dropwise with 55 μL methanesulfonyl chloride and 85 μL pyridine and the resulting mixture was stirred at room temperature for 2 days to give, after silica gel chromatog., 112 mg N-[4-(4-chlorophenyl)-2,2-dimethyl-2H-1,3-benzoxazin-7-yl]methanesulfonamide (II). II in vitro inhibited the binding of [3H]aldosterone to the cytosol fraction of rat kidney with Ki ≤0.5 μM.

IT 1110662-23-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of fused bicyclic compds. as mineralocorticoid receptor antagonists or aldosterone agonists)

RN 1110662-23-1 CAPLUS
CN Benzamide, 4-chloro-2-fluoro-6-hydroxy- (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:384923 CAPLUS
DN 146:401830
TI Preparation of N-acylheterocycles as histone deacetylase (HDAC) inhibitors.
IN Dobler, Marcus Rolf; Grob, Jonathan E.; Patnaik, Anup; Radetich, Branko; Shultz, Michael; Zhu, Yanyi
PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SO PCT Int. Appl., 117pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007038459	A2	20070405	WO 2006-US37358	20060925
	WO 2007038459	A3	20070712		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

				US 2005-720900P	P 20050927
				US 2005-754960P	P 20051228
AU 2006294850	A1	20070405	AU 2006-294850		20060925
				US 2005-720900P	P 20050927
				US 2005-754960P	P 20051228
				WO 2006-US37358	W 20060925
CA 2623034	A1	20070405	CA 2006-2623034		20060925
				US 2005-720900P	P 20050927
				US 2005-754960P	P 20051228
				WO 2006-US37358	W 20060925
EP 1996550	A2	20081203	EP 2006-804134		20060925
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
				US 2005-720900P	P 20050927
				US 2005-754960P	P 20051228
				WO 2006-US37358	W 20060925
JP 2009510073	T	20090312	JP 2008-533498		20060925
				US 2005-720900P	P 20050927
				US 2005-754960P	P 20051228
				WO 2006-US37358	W 20060925
IN 2008DN02492	A	20080627	IN 2008-DN2492		20080325
				US 2005-720900P	P 20050927
				WO 2006-US37358	W 20060925
MX 2008004200	A	20080415	MX 2008-4200		20080327
				US 2005-720900P	P 20050927
				US 2005-754960P	P 20051228
				WO 2006-US37358	W 20060925
US 20080255149	A1	20081016	US 2008-88367		20080327
				US 2005-720900P	P 20050927
				US 2005-754960P	P 20051228
				WO 2006-US37358	W 20060925
CN 101282932	A	20081008	CN 2006-80037636		20080410
				US 2005-720900P	P 20050927
				US 2005-754960P	P 20051228
				WO 2006-US37358	W 20060925
KR 2008054417	A	20080617	KR 2008-710031		20080425
				US 2005-720900P	P 20050927
				US 2005-754960P	P 20051228
				WO 2006-US37358	W 20060925

OS MARPAT 146:401830

AB Title compds. [I; R1 = H, NH2, NHR6, SR6, SOR6, O, OR6; R2, R3 = H, (heterosubstituted) alkyl, alkenyl; X = atoms to form (heterosubstituted) cycloalkyl, cycloalkenyl, aryl, heterocycloalkyl, heteroaryl, polyheterocyclyl; n, p = 0-4; R4 = H, (heterosubstituted) alkyl, alkylaryl, alkoxy, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, etc.; R5 = H, O, halo, alkoxy, (heterosubstituted) alkyl; R6 = H, alkyl], were prepared Thus, title compound (R)-2-amino-1-(4-biphenyl-3-yl-3,6-dihydro-2H-pyridin-1-yl)-3-(4-chlorophenyl)propan-1-one was prepared from 1-Boc-4-piperidone, 3-biphenylboronic acid, and Boc-4-chloro-D-phenylalanine in 5 steps. I inhibited HDAC with IC50 = 0.005-100 μM.

IT 932719-11-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-acylheterocycles as histone deacetylase inhibitors)
RN 932719-11-4 CAPLUS
CN 1-Propanone, 2-amino-3-(2,4-dichloro-6-hydroxyphenyl)-1-(1,3-dihydro-2H-isoindol-2-yl)- (CA INDEX NAME)



L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:729486 CAPLUS
DN 145:377150
TI Facile regio- and stereoselective carbon-carbon coupling of phenol derivatives with aryl aziridines. [Erratum to document cited in CA145:124402]
AU Pineschi, Mauro; Bertolini, Ferruccio; Crotti, Paolo; Macchia, Franco
CS Dipartimento di Chimica Bioorganica e Biofarmacia, Universita di Pisa, Pisa, 56126, Italy
SO Organic Letters (2006), 8(19), 4383
CODEN: ORLEF7; ISSN: 1523-7060
PB American Chemical Society
DT Journal
LA English
AB On page 2627, the chemical structures of compds. 2A, 2B, and 2C in Scheme 1 are incorrect; the correct version of scheme 1 is given. On page 2627, the chemical structures of compds. 2A, 2B, and 2C in Scheme 2 are incorrect; the correct version of the compds. are given. On page 2628, in column 1, in lines 6 and 7, "a high syn selectivity" should read "a high anti stereoselectivity". On page 2628, in column 2, in paragraph 2, in line 16, "and syn stereoselectivity (entries 1-3, Table 1)" should read "and anti stereoselectivity (entries 1-3, Table 1)". On page 2628, in column 2, in paragraph 3, in line 39, "complete syn stereoselectivity" should read "complete anti stereoselectivity". On page 2629, in column 2 of Table 1, the first six entries relative to aziridine configuration as "(R)" should read "(S)". On page 2629, the title of the seventh column of Table 1 should read "anti/syn". On page 2629, in the sixth column of Table 1, the chemical structure of compound 3fd is incorrect; the correct chemical structure is given. On page 2630, the chemical reaction scheme on top of Table 2 is incorrect; the correct version of the reaction scheme is given. On page 2630, in column 2 in paragraph 2, in line 2, "trans 2,3-substituted indoline 6fd" should read "cis 2,3-substituted indoline 6fd". On page 2630, in column 2, in paragraph 2, in line 12, "retention of configuration at the cleaved center" should read "inversion of configuration at the cleaved center".
IT 897961-20-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(regio- and stereoselective carbon-carbon coupling of phenol derivs. with arylaziridines (Erratum))
RN 897961-20-5 CAPLUS
CN Phenol, 2-(2-amino-1,2-diphenylethyl)-3,5-dimethoxy- (CA INDEX NAME)



L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:429502 CAPLUS
DN 145:124402
TI Facile regio- and stereoselective carbon-carbon coupling of phenol derivatives with aryl aziridines
AU Pineschi, Mauro; Bertolini, Ferruccio; Crotti, Paolo; Macchia, Franco
CS Dipartimento di Chimica Bioorganica e Biofarmacia, Universita di Pisa, Pisa, 56126, Italy
SO Organic Letters (2006), 8(12), 2627-2630
CODEN: ORLEF7; ISSN: 1523-7060
PB American Chemical Society
DT Journal
LA English
OS CASREACT 145:124402
AB A chemo-, regio-, and stereoselective direct carbon-carbon coupling of readily available aryl borates with N-protected arylaziridines provides a method for the synthesis of new 2-(o-hydroxyaryl)-2-arylethylamines which can be used, in a novel annulation sequence, to give stereodefined substituted 3-arylindolines.
IT 897961-20-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(regio- and stereoselective carbon-carbon coupling of phenol derivs. with arylaziridines)
RN 897961-20-5 CAPLUS
CN Phenol, 2-(2-amino-1,2-diphenylethyl)-3,5-dimethoxy- (CA INDEX NAME)



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:859383 CAPLUS
DN 142:373475
TI Transition metal catalyzed sodium borotritide reductions: a useful alternative to the use of tritium gas
AU Tang, Yui S.; Liu, Wensheng; Chaudhary, Ashok; Melillo, David G.; Dean, Dennis C.
CS Merck Research Laboratories, Rahway, NJ, 07065, USA
SO Synthesis and Applications of Isotopically Labelled Compounds, Proceedings of the International Symposium, 8th, Boston, MA, United States, June 1-5,

2003 (2004), Meeting Date 2003, 71-74. Editor(s): Dean, Dennis C.; Filer, Crist N.; McCarthy, Keith E. Publisher: John Wiley & Sons Ltd., Chichester, UK.
CODEN: 69FZAZ; ISBN: 0-470-86365-X
DT Conference
LA English
OS CASREACT 142:373475
AB Sodium borotritide can be used in combination with transition metal additives for reduction of aryl halides and olefins as an alternative to traditional catalytic tritium gas reduction This methodol. produces high specific activity product, demonstrates excellent chemoselectivity, and eliminates undesired tritium exchange.
IT 849367-52-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(chemoselective preparation of tritium labeled arenes via reductive dehalogenation of arylhalides with sodium borotritide and palladium acetate)
RN 849367-52-8 CAPLUS
CN Phen-2-t-ol, 6-(aminomethyl)-3,5-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:2832 CAPLUS
DN 140:59400
TI Preparation of aminoalkylphenols as antimalarials active against drug-resistant Plasmodia.
IN Dorn, Conrad P.; Powles, Mary Ann; Walsh, Thomas F.; Wyvratt, Matthew J.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004000783	A1	20031231	WO 2003-US19393	20030620

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2002-391361P	P 20020624
CA 2490243	A1	20031231	CA 2003-2490243	20030620
			US 2002-391361P	P 20020624
			WO 2003-US19393	W 20030620
AU 2003251574	A1	20040106	AU 2003-251574	20030620
AU 2003251574	B2	20090122		
			US 2002-391361P	P 20020624
			WO 2003-US19393	W 20030620
EP 1517879	A1	20050330	EP 2003-761147	20030620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
			US 2002-391361P	P 20020624
			WO 2003-US19393	W 20030620
JP 2005534676	T	20051117	JP 2004-515965	20030620
			US 2002-391361P	P 20020624
			WO 2003-US19393	W 20030620
US 20050234265	A1	20051020	US 2004-511661	20041018
			US 2002-391361P	P 20020624
			WO 2003-US19393	W 20030620

OS MARPAT 140:59400

AB Title compds. [I; R5, R1a, R1 = H, alkyl, halo, alkoxy, cycloalkyl, aryl, trihalovinyl, said aryl optionally substituted with 1-3 Ra; R2 = H, alkyl, C3-10 cycloalkyl; taken together with any intervening atoms can form a 3-7 membered carbocyclyl, heterocyclyl unsatd., said heterocyclic ring containing 1-2 O, CO, S, SO, SO2, N, NR2a and optionally substituted by 1-3 Ra; R2a = H , alkyl; R3, R3a = H , halo, alkyl, C3-10 cycloalkyl, aryl, said aryl and alkyl optionally substituted with 1-3 Ra; R3R3a = atoms to form a 3-7 membered carbocyclyl, heterocyclyl saturated or unsatd., said heterocyclic ring containing 1-2 O, CO, S, SO, SO2, N, NR2a and optionally substituted by 1-3 Ra; R4 = H, halo, alkyl, trihaloalkyl; Ra = alkoxy, alkyl, CF3, NO2, amino, cyano, alkylamino, halo; n = 1-3], were prepared Thus, 3-tert-butylphenol and N-hydroxymethyl-2-chloroacetamide were added in portions to a vigorously stirred solution of AcOH and H2SO4 at 0°; the reaction mixture was allowed to warm to room temperature over several hours, and stirring was maintained for a total of 20 h to give a product which was heated in aqueous HCl at 85° for 3 h to give 2-aminomethyl-5-tert-butylphenol hydrochloride. I inhibited Plasmodium falciparum with IC50<1 μg/mL.

IT 51571-04-1P 84210-35-5P 639069-25-3P
639069-26-4P 639070-00-1P 639070-07-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoalkylphenols as antimalarials active against drug-resistant Plasmodia)

RN 51571-04-1 CAPLUS

CN Phenol, 2-(aminomethyl)-3,5-bis(1,1-dimethylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 84210-35-5 CAPLUS
CN Phenol, 2-(aminomethyl)-3,5-bis(1,1-dimethylethyl)- (CA INDEX NAME)



RN 639069-25-3 CAPLUS
CN [1,1'-Biphenyl]-3-ol, 2-(aminomethyl)-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 639069-26-4 CAPLUS
CN [1,1'-Biphenyl]-3-ol, 2-(aminomethyl)-5-(1,1-dimethylethyl)-4'-methyl- (CA INDEX NAME)



RN 639070-00-1 CAPLUS
CN Phenol, 2-(2-aminoethyl)-3,5-bis(1,1-dimethylethyl)- (CA INDEX NAME)



RN 639070-07-8 CAPLUS
CN Phenol, 2-(1-aminoethyl)-3,5-bis(1,1-dimethylethyl)- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:857716 CAPLUS
DN 138:197738
TI A structurally characterized monomeric Mn(IV) complex in a discrete N2O4 coordination environment
AU Rajendiran, T. M.; Kampf, Jeff W.; Pecoraro, Vincent L.
CS Department of Chemistry, The University of Michigan, Ann Arbor, MI, 48109-1055, USA
SO Inorganica Chimica Acta (2002), 339, 497-502
CODEN: ICHAA3; ISSN: 0020-1693
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 138:197738
AB From the reaction of Mn(III)(OAc)3 with (3,5-di-tert-butyl-2-hydroxyphenylmethyliminomethyl)3,5-di-tert-butyl-phenol (H2dbpip) in MeCN, dark brown crystals of compound Bis[(3,5-di-tert-butyl-2-hydroxyphenylmethyliminomethyl)3,5-di-tert-butylphenolato]manganese (IV), Mn(IV)(dbpip)2 (1) were obtained upon slow evaporation of the solvent. The structural assignments of 1, that were made in part by elemental anal. and magnetic susceptibility, were confirmed by single crystal x-ray diffraction studies which revealed that compound 1 crystallizes in the monoclinic, space group C2/c with a cell dimensions a = 49.746(8), b = 12.682(2), c 19.497(3) Å,α 90, β 94.240(3), γ 90°. Cyclic voltammetry reveals a quasi reversible redox wave corresponding to the Mn(III)/Mn(IV) couple. The EPR spectrum at 4 K consists of strong and weak signals near g = 2 and 4, resp. A comparison of the EPR spectrum to there obtained for other Mn(IV)N2O4 complexes reveals that 1 is a rare example of an axial Mn(IV) species with D«hν.
IT 84210-35-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(for preparation of hydroxyphenylmethyliminomethylphenol)
RN 84210-35-5 CAPLUS
CN Phenol, 2-(aminomethyl)-3,5-bis(1,1-dimethylethyl)- (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1998:474387 CAPLUS
DN 129:149242
OREF 129:30425a,30428a
TI Solid-phase synthesis of muramyl dipeptides on isomeric trialkoxybenzylamine resins
AU Kohlbau, Hans-Juergen; Tschakert, Jochen; Al-Qawasmeh, Raed A.; Nizami, Tanveer Ahmad; Malik, Abdul; Voelter, Wolfgang
CS Abteilung Physikalische Biochemie, Physiologisch-Chemisches Institut, Universitaet Tuebingen, Tuebingen, D-72076, Germany
SO Zeitschrift fuer Naturforschung, B: Chemical Sciences (1998), 53(7), 753-764
CODEN: ZNBSEN; ISSN: 0932-0776
PB Verlag der Zeitschrift fuer Naturforschung
DT Journal
LA German
AB Isomeric trialkoxybenzylamine resins are developed by coupling of phthalimidomethyl-substituted 3,5-dimethoxyphenols to Merrifield resin and subsequent treatment with N2H4. The generated benzylamine function allows DCC coupling with the carboxyl function of amino acids and peptides which are removed as amides after treatment with CF3CO2H. These trialkoxybenzylamine resins allow expeditious syntheses of peptide amides and glycopeptide amides as is demonstrated for muramyl peptides and analogs.
IT 130632-99-4DP, resin-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(solid-phase synthesis of muramyl dipeptides on isomeric alkoxybenzylamine resins)
RN 130632-99-4 CAPLUS
CN Phenol, 2-(aminomethyl)-3,5-dimethoxy- (CA INDEX NAME)



L4 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1990:632031 CAPLUS
DN 113:232031

OREF 113:39169a,39172a
TI Acid-labile anchoring linkages for solid phase synthesis of C-terminal asparagine peptides using the Fmoc strategy
AU Shao, Jun; Li, You He; Voelter, Wolfgang
CS Inst. Biochem., Univ. Tuebingen, Tuebingen, Germany
SO International Journal of Peptide & Protein Research (1990), 36(2), 182-7
CODEN: IJPPC3; ISSN: 0367-8377
DT Journal
LA English
OS CASREACT 113:232031
AB Two acid-labile substituted benzylamine type anchoring linkages, 4-benyloxy-2,6-dimethoxybenzylamine and 2-benzyloxy-4,6-dimethoxybenzylamine, for solid phase synthesis of peptide amides were prepared The Nα-9-fluorenylmethyloxycarbonyl (Fmoc) amino acids could be easily attached to the resins with DCC/HOBt (loading 0.5-0.6 mmol/g resin). After final removal of the Nα-protecting groups, treatment with CF3CO2H (50-95%) yielded amino acid and peptide amides in high purity. The synthesis of thymulin (pGlu-Ala-Lys-Ser-Gln-Gly-Ser-Asn-OH) demonstrated that these two resins with anchoring linkages are well suited for the synthesis of C-terminal asparagine peptides using protected aspartic acid derivs. as starting materials.
IT 130632-99-4DP, resin-bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and solid-phase peptide coupling reactions of, peptide amides from)
RN 130632-99-4 CAPLUS
CN Phenol, 2-(aminomethyl)-3,5-dimethoxy- (CA INDEX NAME)



L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1989:566101 CAPLUS
DN 111:166101
OREF 111:27485a,27488a
TI Metal complexes of antiinflammatory drugs. Part VI. 2-Aminomethyl-4-(1,1-dimethylethyl)-6-iodophenol (MK-447) complex of copper(II)
AU Bury, A.; Underhill, A. E.; Fleet, M. B.; Keymer, P. J.; Stevens, A.; Gomm, P. S.
CS Chem. Dep., Univ. Coll. North Wales, Bangor, UK
SO Inorganica Chimica Acta (1989), 158(2), 181-4
CODEN: ICHAA3; ISSN: 0020-1693
DT Journal
LA English
AB The preparation and properties of Cu(MK)2.2H2O are reported for the anti-inflammatory drug 2-aminomethyl-4-(1,1-dimethylethyl)-6-iodophenol (HMK). The diffuse reflectance spectra and magnetic moments are consistent with a tetragonally distorted pseudooctahedral environment around the Cu(II) ion. The IR spectra indicate that MK acts as a chelate

monoanionic ligand with coordination involving the phenolate O atom and the N atom of the aminomethyl group. The Cu(II) complex exhibits marked superoxide dismutase activity in the nitroblue tetrazolium assay.

IT 122890-69-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(IR spectrum and superoxide dismutase activity of)

RN 122890-69-1 CAPLUS

CN Phenol, 2-(aminomethyl)-5-(1,1-dimethylethyl)-3-iodo-, conjugate acid (1:1) (CA INDEX NAME)



L4 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1988:140707 CAPLUS

DN 108:140707

OREF 108:22935a,22938a

TI Triboelectrifying material for charging electrostatographic toner

IN Fukumoto, Hiroshi; Tanaka, Katsuhiko; Kawagishi, Yoji

PA Canon K. K., Japan; Orient Chemical Industries, Ltd.

SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61160763	A	19860721	JP 1985-819	19850109
JP 06046314	B	19940615		
			JP 1985-819	19850109

AB The triboelectrifying material has on its surface a metal-salicylamine or alkylsalicylamine complex. The complex may be coated on carrier particles, on a developing sleeve, or on a developing doctor blade. An Fe powder may be coated with Co-salicylamine complex to give the title material. The material shows improved durability in providing images with constant d.

IT 84210-35-5D, complexes with transition metals
RL: USES (Uses)
(triboelectrifying agents, for electrostatog. toners, with improved durability)

RN 84210-35-5 CAPLUS

CN Phenol, 2-(aminomethyl)-3,5-bis(1,1-dimethylethyl)- (CA INDEX NAME)



L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1983:53306 CAPLUS
DN 98:53306
OREF 98:8181a,8184a
TI The use of sterically hindered benzylamines in the Sommelet reaction
AU Stokker, G. E.; Schultz, E. M.
CS Merck Sharp Dohme Res. Lab., West Point, PA, 19486, USA
SO Synthetic Communications (1982), 12(11), 847-53
CODEN: SYNCAV; ISSN: 0039-7911
DT Journal
LA English
OS CASREACT 98:53306
AB Amines I (R = H, Me; R1 = H, halo, Me; R2 = H, alkyl, OMe; R3 = alkyl, H, Cl; R4 = H, alkyl, Cl, OMe) were converted to the resp. aldehydes II. Thus, I (R = R2 = R4 = H, R1 = iodo, R3 = CMe3) hydrochloride was heated with hexamethylenetetramine in aqueous HOAc to give II.
IT 84210-35-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(Sommelet reaction of)
RN 84210-35-5 CAPLUS
CN Phenol, 2-(aminomethyl)-3,5-bis(1,1-dimethylethyl)- (CA INDEX NAME)



L4 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1980:620454 CAPLUS
DN 93:220454
OREF 93:35187a,35190a
TI 2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution
AU Stokker, G. E.; Deana, A. A.; DeSolms, S. J.; Schultz, E. M.; Smith, R. L.; Cragoe, E. J., Jr.; Baer, J. E.; Ludden, C. T.; Russo, H. F.; et al.
CS Merck Inst. Ther. Res., West Point, PA, 19486, USA
SO Journal of Medicinal Chemistry (1980), 23(12), 1414-27
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 93:220454
AB A series of .apprx.100 2-(aminomethyl)phenols was synthesized and tested in rats and dogs for saluretic and diuretic activity; several were highly active on i.v. or oral administration. The most active were

4-alkyl-6-halo derivs., especially 2-(aminomethyl)-4-(1,1-dimethylethyl)-6-iodophenol (I). I also had significant antihypertensive, topical saluretic, and antiinflammatory activity.

IT 51571-04-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as potential diuretic or saluretic agent)

RN 51571-04-1 CAPLUS

CN Phenol, 2-(aminomethyl)-3,5-bis(1,1-dimethylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1978:423271 CAPLUS

DN 89:23271

OREF 89:3617a,3620a

TI Infrared spectra of 1,2,3,5-tetrasubstituted benzene derivatives

AU Varsanyi, G.; Horvath, G.; Imre, L.; Schawartz, J.; Sohar, P.; Soti, F.

CS Tech. Univ. Budapest, Budapest, Hung.

SO Acta Chimica Academiae Scientiarum Hungaricae (1977), 93(3-4), 315-55
CODEN: ACASA2; ISSN: 0001-5407

DT Journal

LA English

AB The ring vibration in the IR of one-hundred and fifteen 1,2,3,5-tetrasubsituted benzenes are classified into 3 groups, depending on whether all 4 substituents are light or 1 or 2 of them are heavy (consts. Cl, Br and/or I). The substituent effects on the fundamental vibrations of the benzene ring and their intensities, and the character of the bands associated with internal substituent vibrations are discussed.

IT 62827-48-9
RL: PRP (Properties)
(IR of)

RN 62827-48-9 CAPLUS

CN Benzamide, 2-hydroxy-4,6-dimethoxy- (CA INDEX NAME)



L4 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1977:189650 CAPLUS
DN 86:189650
OREF 86:29737a,29740a
TI Synthesis of natural dibenzo-α-pyrones, II. Synthesis of alternariol and alternariol 9-methyl ether
AU Soti, Ferenc; Incze, Maria; Kajtar-Peredy, Maria; Baitz-Gacs, Eszter; Imre, Lajos; Farkas, Lorand
CS Cent. Res. Inst. Chem., Hung. Acad. Sci., Budapest, Hung.
SO Chemische Berichte (1977), 110(3), 979-84
CODEN: CHBEAM; ISSN: 0009-2940
DT Journal
LA German
AB I (R = OH), a key intermediate in the synthesis of arternariol (II, R1 = R2 = H), was prepared in 6 steps from 2,4,6-Br(O2N)2C6H2Me by successively replacing the MeO groups and finally oxidizing the Me group. The Hurtley condensation, used to cyclize I (R = OH) with 5-MeC6H3(OH)2-1,3 to give II (R1 = R2 = H), was extended to the corresponding amide I (R = NH2) to give 25% II (R1 = R2 = Me), which was completely demethylated to give 81% II (R1 = R2 = H) or partially demethylated to give 73% II (R1 = Me, R2 = H). I (R = NH2) was prepared in 3 steps from 2,4,6-Br(O2N)2C6H2NH2.
IT 62827-48-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 62827-48-9 CAPLUS
CN Benzamide, 2-hydroxy-4,6-dimethoxy- (CA INDEX NAME)



L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1974:120533 CAPLUS
DN 80:120533
OREF 80:19395a,19398a
TI Treating edema and hypertension using certain 2-aminoethylphenols
IN Cragoe, Edward J., Jr.; Schultz, Everett M.
PA Merck and Co., Inc.
SO U.S., 9 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3794734	A	19740226	US 1971-120730	19710303
	US 3979361	A	19760907	US 1975-600990	19750801
				US 1971-120730 A2	19710303
				US 1974-444200 A2	19740220
	US 4044153	A	19770823	US 1976-684138	19760507
				US 1971-120730 A2	19710303
				US 1974-444200 A2	19740220
				US 1975-600990 A1	19750801

PATENT FAMILY INFORMATION:

FAN 1977:29478

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 3979361	A	19760907	US 1975-600990		19750801
				US 1971-120730	A2	19710303
				US 1974-444200	A2	19740220
	US 3794734	A	19740226	US 1971-120730		19710303
	US 4044153	A	19770823	US 1976-684138		19760507
				US 1971-120730	A2	19710303
				US 1974-444200	A2	19740220
				US 1975-600990	A1	19750801

FAN 1977:551847

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 4044153	A	19770823	US 1976-684138		19760507
				US 1971-120730	A2	19710303
				US 1974-444200	A2	19740220
				US 1975-600990	A1	19750801
	US 3794734	A	19740226	US 1971-120730		19710303
	US 3979361	A	19760907	US 1975-600990		19750801
				US 1971-120730	A2	19710303
				US 1974-444200	A2	19740220

AB 2-(Aminomethyl)phenols (I; e.g., R = R2 = R3 = Cl, R1 = H; R = Me, R1 = R3 = H, R2 = Me3C; R = H, R1 = R3 = MeO, R2 = Cl), useful in the treatment of adema and hypertension, were prepared Thus, treatment of 2,4,5-Cl3C6H2OH and ClCH2-CONHCH2OH with H2SO4 gave the amide (II) which, when treated with ethanolic HCl, gave I (R = R2 = R3 = Cl, R1 = H). About 24 I were prepared similarly.

IT 51571-04-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 51571-04-1 CAPLUS

CN Phenol, 2-(aminomethyl)-3,5-bis(1,1-dimethylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1917:16235 CAPLUS

DN 11:16235

OREF 11:3259i,3260a-c

TI Formation of hydrocoumarin derivatives (dihydro-α-benzopyrones) from phloroglucinol

AU Fischer, Emil; Nouri, Osman

SO Berichte der Deutschen Chemischen Gesellschaft (1917), 50, 693-701

CODEN: BDCGAS; ISSN: 0365-9496
DT Journal
LA Unavailable
AB through J. Chemical Society 112, I, 469-70. When cinnamonitrile and phloroglucinol (a) in Et2O are mixed with powdered ZnCl2, chilled and saturated with HCl there gradually seps. the granular HCl salt of the intermediate imine, (HO)2C6H2.CHPh.CH2.C(:NH.HCl).O, which on heating with H2O yields 5,7-dihydroxy-4-phenyl-3,4-dihydro-1,2-benzopyrone, (HO)2C6H2.CHPh.CH2.CO.O, slender needles, m. 211°, whose diacetate m. 147-8°. The compound can also be obtained by reduction of the dihydroxyphenylbenzopyrone. With CH2N2 it gives the 5,7-dimethoxy compound (b), long needles or stout prisms, m. 131-2°, converted into β-phenyl-β-2,4,6-trimethoxyphenylpropionic acid, columns or tablets, m. 156-7°, by hydrolyzing with aqueous alc. NaOH, adding the Et2O extract to CH2N2 in cold Et2O and finally hydrolyzing the resulting Me ester. With NH8 in MeOH at 50-60° in a sealed tube (b) yields β-phenyl-β-2-hydroxy-4,6-dimethoxyphenylpropionamide, m. 185-6° (decomposition), and with warm PhNHNH2 it gives the phenylhydrazide, long prisms, m. 171-2°. p-Coumaronitrile and (a) similarly give 5,7-dihydroxy-4-hydroxyphenyl-3,4-dihydro-1,2-benzopyrone, slender needles, m. indefinitely about 270°. PhC.tplbond.CCO2Et and (a) give a good yield of 5,7-dihydroxy-4-phenyl-1,2-benzopyrone, m. 238-9°. The above m. ps. are corrected
IT 861324-27-8P, Melilotamide, 4,6-dimethoxy-β-phenyl-
RL: PREP (Preparation)
(preparation of)
RN 861324-27-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED